• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助化疗为无法手术的局部晚期乳腺癌创造了手术机会。

Neoadjuvant Chemotherapy Creates Surgery Opportunities For Inoperable Locally Advanced Breast Cancer.

机构信息

Center of Breast Disease, Southwest Hospital, The Third Military Medical University, Chongqing, 400038, China.

Department of Thyroid Breast Surgery, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, 637000, China.

出版信息

Sci Rep. 2017 Mar 22;7:44673. doi: 10.1038/srep44673.

DOI:10.1038/srep44673
PMID:28327615
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5361098/
Abstract

Neoadjuvant chemotherapy (NAC), the systematic chemotherapy given to patients with locally advanced and inoperable breast caner, has been proven to be of great clinical values. Many scientific reports confirmed NAC could effectively eliminate sub-clinical disseminated lesions of tumor, and improve long-term and disease-free survival rate of patients with locally advanced breast cancer (LABC); however, up to now, LABC is still a serious clinical issue given improved screening and early diagnosis. This study, with main focus on inoperable LABC, investigated the values of NAC in converting inoperable LABC into operable status and assessed the prognosis. Sixty-one patients with inoperable LABC were initially treated with neoadjuvant chemotherapy; their local conditions were improved to operable status. Radical surgery was exerted on 49 patients. Original chemotherapy was performed after surgery, followed by local radiotherapy. And endocrine therapy was optional according to the hormone receptor status. The quality of life for most patients with skin diabrosis was obviously improved because their local conditions were under control. For all recruited cases, the survival duration and life quality were significantly improved in patients who finished both NAC and surgery compared to those who did not. Further more, this study demonstrates improved prognostic consequences.

摘要

新辅助化疗(NAC),即给予局部晚期和不可手术的乳腺癌患者的系统性化疗,已被证明具有重要的临床价值。许多科学报告证实,NAC 可有效消除肿瘤的亚临床播散病变,并提高局部晚期乳腺癌(LABC)患者的长期无病生存率;然而,迄今为止,尽管通过改善筛查和早期诊断,LABC 仍然是一个严重的临床问题。本研究主要关注不可手术的 LABC,调查了 NAC 将不可手术的 LABC 转化为可手术状态的价值,并评估了预后。61 例局部晚期不可手术的 LABC 患者最初接受新辅助化疗;他们的局部情况改善至可手术状态。49 例患者接受了根治性手术。术后进行原始化疗,然后进行局部放疗。根据激素受体状态,内分泌治疗是可选的。由于局部情况得到控制,大多数皮肤溃疡患者的生活质量明显改善。对于所有入组病例,与未完成 NAC 和手术的患者相比,完成 NAC 和手术的患者的生存时间和生活质量均显著提高。此外,本研究表明预后结果得到改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8062/5361098/8a06cfd93b6e/srep44673-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8062/5361098/5f2a1bcd4fee/srep44673-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8062/5361098/5d6c6592dc4f/srep44673-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8062/5361098/8a06cfd93b6e/srep44673-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8062/5361098/5f2a1bcd4fee/srep44673-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8062/5361098/5d6c6592dc4f/srep44673-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8062/5361098/8a06cfd93b6e/srep44673-f3.jpg

相似文献

1
Neoadjuvant Chemotherapy Creates Surgery Opportunities For Inoperable Locally Advanced Breast Cancer.新辅助化疗为无法手术的局部晚期乳腺癌创造了手术机会。
Sci Rep. 2017 Mar 22;7:44673. doi: 10.1038/srep44673.
2
Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer.高血管密度预示乳腺癌化疗的完全病理缓解及晚期预后
Clin Breast Cancer. 2016 Dec;16(6):e193-e201. doi: 10.1016/j.clbc.2016.06.007. Epub 2016 Jun 23.
3
Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.保乳手术与改良根治术在局部晚期乳腺癌新辅助化疗患者中的肿瘤安全性比较。
J Surg Oncol. 2013 Dec;108(8):531-6. doi: 10.1002/jso.23439. Epub 2013 Sep 30.
4
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.曲妥珠单抗辅助治疗局部晚期或炎性乳腺癌的 NeOAdjuvant Herceptin(NOAH)研究中,接受新辅助治疗后行手术治疗的 HER2 阳性患者。
Eur J Surg Oncol. 2011 Oct;37(10):856-63. doi: 10.1016/j.ejso.2011.07.003. Epub 2011 Aug 16.
5
Neoadjuvant chemotherapy in locally advanced breast cancer.局部晚期乳腺癌的新辅助化疗
J Coll Physicians Surg Pak. 2014 Nov;24(11):845-8.
6
Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.局部晚期乳腺癌新辅助化疗早期失败的临床病理特征。
Cancer Chemother Pharmacol. 2014 Sep;74(3):521-9. doi: 10.1007/s00280-014-2542-5. Epub 2014 Jul 22.
7
A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.基于新辅助化疗后雌激素受体表达和 Ki-67 值相结合的预后模型预测局部晚期乳腺癌的临床结局:对先前报道的患者队列的扩展和分析。
Eur J Surg Oncol. 2013 Oct;39(10):1046-52. doi: 10.1016/j.ejso.2013.06.024. Epub 2013 Jul 26.
8
Management of locally advanced breast cancer. Mini-review.局部晚期乳腺癌的管理。小型综述。
Minerva Chir. 2007 Aug;62(4):249-55.
9
Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.马来西亚一家三级医院对局部晚期乳腺癌进行新辅助化疗的情况
Asian Pac J Cancer Prev. 2011;12(1):157-62.
10
IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer--results of a case series after 5-year follow-up.保乳手术后新辅助化疗局部晚期乳腺癌中预期瘤床推量放疗(IOERT)——5 年随访后的病例系列结果。
Int J Cancer. 2015 Mar 1;136(5):1193-201. doi: 10.1002/ijc.29064. Epub 2014 Jul 10.

引用本文的文献

1
Supraclavicular Lymph Node Dissection in Breast Cancer with Synchronous Supraclavicular Metastases: A Systematic Review and Network Meta-Analysis.伴有同步锁骨上转移的乳腺癌患者的锁骨上淋巴结清扫术:一项系统评价和网状Meta分析
Cancers (Basel). 2025 Jun 21;17(13):2081. doi: 10.3390/cancers17132081.
2
Prognostic Significance of Peripheral Blood Parameters as Predictor of Neoadjuvant Chemotherapy Response in Breast Cancer.外周血参数作为乳腺癌新辅助化疗反应预测指标的预后意义
Int J Mol Sci. 2025 Mar 12;26(6):2541. doi: 10.3390/ijms26062541.
3
Superior Survival and Lower Recurrence Outcomes with Breast-Conserving Surgery Compared to Mastectomy Following Neoadjuvant Therapy in 607 Breast Cancer Patients.

本文引用的文献

1
Neoadjuvant therapy for breast cancer.乳腺癌的新辅助治疗。
J Surg Oncol. 2010 Mar 15;101(4):283-91. doi: 10.1002/jso.21446.
2
Neoadjuvant chemotherapy for breast cancers: current recommendations and future directions.乳腺癌的新辅助化疗:当前建议与未来方向
Eur J Cancer. 2009 Sep;45 Suppl 1:368-70. doi: 10.1016/S0959-8049(09)70052-8.
3
Neoadjuvant chemotherapy for locally advanced breast cancer.局部晚期乳腺癌的新辅助化疗
在607例乳腺癌患者中,新辅助治疗后保乳手术与乳房切除术相比,具有更高的生存率和更低的复发率。
Cancers (Basel). 2025 Feb 24;17(5):766. doi: 10.3390/cancers17050766.
4
Advances in analytical approaches for background parenchymal enhancement in predicting breast tumor response to neoadjuvant chemotherapy: A systematic review.用于预测乳腺肿瘤对新辅助化疗反应的背景实质强化分析方法的进展:一项系统综述。
PLoS One. 2025 Mar 7;20(3):e0317240. doi: 10.1371/journal.pone.0317240. eCollection 2025.
5
Correlation of Histopathological and Radiological Response Patterns and Their Prognostic Implications in Breast Cancer After Neoadjuvant Chemotherapy.新辅助化疗后乳腺癌组织病理学与放射学反应模式的相关性及其预后意义
Breast Cancer (Dove Med Press). 2024 Dec 31;16:1005-1017. doi: 10.2147/BCTT.S495553. eCollection 2024.
6
The Potential of Plant Polysaccharides and Chemotherapeutic Drug Combinations in the Suppression of Breast Cancer.植物多糖与化疗药物联合抑制乳腺癌的潜力。
Int J Mol Sci. 2024 Nov 13;25(22):12202. doi: 10.3390/ijms252212202.
7
Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials.不可手术局部晚期乳腺癌的诊治现状及无机纳米材料的应用价值。
J Nanobiotechnology. 2024 Jun 25;22(1):366. doi: 10.1186/s12951-024-02644-9.
8
Assessment of the impact of residual tumors at different sites post-neoadjuvant chemotherapy on prognosis in breast cancer patients and development of a disease-free survival prediction model.评估新辅助化疗后不同部位残留肿瘤对乳腺癌患者预后的影响及建立无病生存预测模型。
Ther Adv Med Oncol. 2024 May 9;16:17588359241249578. doi: 10.1177/17588359241249578. eCollection 2024.
9
De-Escalation Surgery in cT3-4 Breast Cancer Patients after Neoadjuvant Therapy: Predictors of Breast Conservation and Comparison of Long-Term Oncological Outcomes with Mastectomy.新辅助治疗后cT3-4期乳腺癌患者的降阶梯手术:保乳的预测因素及与乳房切除术的长期肿瘤学结局比较
Cancers (Basel). 2024 Mar 16;16(6):1169. doi: 10.3390/cancers16061169.
10
Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients.循环肿瘤 DNA 是液体活检的一种变体,在乳腺癌患者的预测和预后中有临床价值。
Int J Mol Sci. 2023 Dec 2;24(23):17073. doi: 10.3390/ijms242317073.
Semin Radiat Oncol. 2009 Oct;19(4):222-8. doi: 10.1016/j.semradonc.2009.05.001.
4
Workup and staging of locally advanced breast cancer.局部晚期乳腺癌的检查与分期
Semin Radiat Oncol. 2009 Oct;19(4):211-21. doi: 10.1016/j.semradonc.2009.05.006.
5
Neoadjuvant chemotherapy for locally advanced breast cancer: a single center experience.局部晚期乳腺癌的新辅助化疗:单中心经验。
Med Oncol. 2010 Jun;27(2):454-8. doi: 10.1007/s12032-009-9233-9. Epub 2009 Jun 2.
6
Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions.局部晚期乳腺癌的新辅助化疗:文献综述与未来方向
Eur J Surg Oncol. 2009 Feb;35(2):113-22. doi: 10.1016/j.ejso.2008.03.015. Epub 2008 May 23.
7
Carcinoma of the Breast. II-Criteria of Operability.乳腺癌。II - 可手术性标准
Ann Surg. 1943 Dec;118(6):1032-51. doi: 10.1097/00000658-194312000-00010.
8
The incidence, indications and outcome for the non-operative management of breast cancer.乳腺癌非手术治疗的发病率、适应证及治疗结果。
J Surg Oncol. 2007 Aug 1;96(2):137-43. doi: 10.1002/jso.20789.
9
Selective mastectomy in the management of locally advanced breast cancer.局部晚期乳腺癌治疗中的选择性乳房切除术
Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1010-7. doi: 10.1016/j.ijrobp.2007.01.013. Epub 2007 Mar 29.
10
Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience.局部晚期原发性乳腺癌的新辅助化疗:诺丁汉经验
Eur J Surg Oncol. 2007 Oct;33(8):972-6. doi: 10.1016/j.ejso.2007.02.005. Epub 2007 Mar 27.